GLP-1 is a 30 amino acid peptide produced by the L cells, enteroendocrine cells of the distal ileum and colon, and GIP is a 4 amino acid peptide produced by the K cells of the duodenum and jejunum
[1] [3] Seek urgent medical attention if you experience: Severe or persistent abdominal pain, especially if radiating to your back Repeated vomiting preventing fluid intake Signs of dehydration (dark urine, dizziness, reduced urination) Contact your GP or prescriber routinely if you experience: Ongoing digestive symptoms affecting your quality of life Significant, persistent weight regain Concerns about resuming treatment If you experience any suspected side effects, you can report them via the MHRA Yellow Card scheme
Additional considerations include: Gastrointestinal effects : Wegovy commonly causes nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
New Medicare and Medicaid access programs could also make a difference, but the details will matter: eligibility, prior authorization, which drugs are included, and whether state Medicaid programs participate
Semaglutide is a research-grade GLP-1 receptor agonist analog studied for its interaction with glucagon-like peptide-1 receptors involved in metabolic signaling, glucose regulation pathways, and appetite-related neuroendocrine activity
